Paper Details

  1. Home
  2. Paper Details

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.

Author: ErossEric, GendollaAstrid, JedynakJakub, RettigantiMallikarjuna, StaufferVirginia L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

People with frequent migraines (8-14 days a month) have more severe symptoms and a greater risk of developing chronic migraines compared to those with less frequent migraines (4-7 days a month). This study looked at whether a medication called galcanezumab was more effective than a placebo in reducing the frequency of migraines to lower levels (4-7 days a month or 0-3 days a month).
Paper Details　
Original Abstract of the Article :
Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8-14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acute treatment overuse versus those with low-frequency EM (LFEM: 4...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161994/

データ提供：米国国立医学図書館（NLM）

Migraine: Shifting Sands of Headache Frequency

Migraine, a debilitating neurological condition, can significantly impact an individual's quality of life. This study explores the intriguing phenomenon of migraine frequency shifts in individuals treated with Galcanezumab, a novel medication for episodic migraine. The researchers investigated the proportions of individuals who experienced a shift from higher-frequency episodic migraine (HFEM) to lower-frequency episodic migraine (LFEM) and very low-frequency episodic migraine (VLFEM) after treatment with Galcanezumab, compared to a placebo group. The study provides valuable insights into the potential benefits of Galcanezumab for managing migraine frequency.

Galcanezumab Offers Hope for Shifting Migraine Sands

The study found that a significantly higher proportion of individuals treated with Galcanezumab experienced a shift from HFEM to LFEM and VLFEM compared to the placebo group. This suggests that Galcanezumab may offer a promising approach to managing migraine frequency and reducing the burden of headache days. The researchers emphasize the need for further research to fully understand the long-term effects of Galcanezumab on migraine frequency and the optimal treatment approach for individuals experiencing various migraine frequencies.

Navigating the Oasis of Migraine Relief

This study offers a glimpse into the potential of Galcanezumab for managing migraine frequency. By shifting the sands of migraine frequency, this medication may offer individuals a path towards a more manageable and fulfilling life. It highlights the importance of personalized treatment approaches and underscores the need for continuous research to further optimize migraine management strategies.

Dr. Camel's Conclusion

This study provides encouraging evidence for the potential of Galcanezumab to shift the sands of migraine frequency. The research emphasizes the importance of exploring innovative treatment options and adapting treatment strategies to individual patient needs. The journey through the desert of migraine management is often complex, but with ongoing research and personalized care, individuals may find solace in the oasis of migraine relief.

Date :
  1. Date Completed 2021-06-01
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34049484

DOI: Digital Object Identifier

PMC8161994

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.